KYAN's mission is to
BRIDGE THE CANCER CARE GAP
by advancing revolutionary technologies
ADDRESSING THE CORE CHALLENGE OF CANCER TREATMENT
There is no silver bullet to treat cancer patients.
Cancer is not a single disease, but rather a group of diseases.
In total there are more than 100 different types of cancers that are dynamically expressed in each patient.
Identifying combinations therapies at different dosages is necessary when searching for the best cancer treatment. However, neither humans nor Big Data AI/ML can efficiently solve for large and complex set of predictions.
Our revolutionary phenotypic response technology is highly efficient in identifying safe and effective drug-dose combinations based on small inputs of data
Prospective experiments that identify the optimal phenotypic response surface across different biological models
SMALL DATA AI
Efficiently solve large and dynamic complex systems through a minimum number of tests
Clinical Decision Support
We are building a Truly Personalized Medicine Solution that will help oncologists give cancer patients the tailored treatments they need
How it works
We separate the tumor cells while still fresh so that the cancer can be tested in its current state
Proprietary Drug Screening
Since any patient sample is limited in cells, we maximize the use with a proprietary design of experiments which gives us the right data to analyze
Our computational method maps each patient’s individual results for highly accurate drug response predictions
Report and Insights
Clinicians receive a clear and comprehensive report to better guide treatment for patients
Benefits of our approach
UNIQUE data and treatments for each patient's as their own cancer cells are used for drug response analysis
VAST number of regimens are evaluated to maximize finding effective treatment
ALL actionable treatments within a drug set can be ranked and compared, including against standard care
How we are different from standard care and other options
SAME treatment for all patients and most will fail, requiring multiple lines of treatment
SMALL chance that patients have identifiable biomarkers matched with therapy (est. < 10%)
LIMITED results when screening single drugs and preselected combinations
New target prioritization
Large search discovery for new targets + combinations
Explore combination discovery for lead targets
Retrospective or prospective studies to support dose optimization within trials
Find biomarker signatures based on phenotypic response curves
Find new combination partners or companion Dx for assets that failed trials
Principal Investigator, Cancer Science Institute of Singapore,
Assoc. Professor and Research Director, Pharmacology, School of Medicine, NUS
Provost’s Chair Professor; Director, N.1 and WisDM; Head, Department of Biomedical Engineering, NUS
UCLA Ben Rich-Lockheed Martin Professor Emeritus
U.S. NAE Member
Academia Sinica Academician
Co-founder of GeneFluidics
Prospective clinical data on KYAN's dose modulation platform presented at the
In this policy, “KYAN Therapeutics” or “we” refers to KYAN Technologies Pte Ltd, a Singapore company, UEN 202226520H (together with our subsidiaries).
KYAN Therapeutics is committed to ensuring the proper protection of all information assets within our possession, and doing so in accordance with the Singapore Personal Data Protection Act (the “PDPA”), the Private Hospitals and Medical Clinics Act, the Ministry of Health’s guidelines, directives and other relevant legislation.
This Personal Data Protection Policy explains how we collect, hold, use, disclose, secure, and otherwise manage all personal information. It describes the types of information we collect and hold, as well as the reasons and methods of accessing and correcting such information.
When you provide us with your personal data, directly or indirectly, you expressly grant consent to KYAN Therapeutics to collect, use, and disclose your personal data to all relevant third parties as laid out in our Personal Data Protection Policy.
The policy herein serves as a supplement and therefore does not supersede or act as a substitute to any other prior consent that you may have provided to KYAN Therapeutics with regard to your personal data. KYAN Therapeutics also reserves all rights granted by the law to collect, use, or disclose your personal data.
What is personal data?
Personal data is any data about an identified individual or an individual who is reasonably identifiable.
Types of Personal Data that may be provided to or collected by KYAN Therapeutics include but are not limited to:
(b) NRIC, passport or other personal identification number;
(c) Telephone number;
(d) Fax number
(e) Mailing address;
(f) E-mail address; and
(g) any other information relating to the individual that has been provided to KYAN Therapeutics.
How do we collect personal data?
We may collect personal data in any of the following scenarios:-
For what purposes do we use and disclose personal information?
KYAN Therapeutics uses the personal information it collects and holds to:
We may also use personal data in circumstances where we are required or authorised by law to do so or where we otherwise have consent of the individual or their representative.
To whom do we disclose personal information?
By contacting or dealing with us, you herein agreed unilaterally that we may disclose an individual’s personal information to the following third parties (including but not limited to) to other health service providers involved in the individual’s treatment or diagnostic services
How do we store and secure personal information?
We store personal and health information in electronic form.
The security of personal and health information is very important to us and we take reasonable steps to protect it from misuse, interference and loss and from unauthorised access, modification or disclosure.
Some of the ways we do this include:
Personal and health information is retained for the period of time determined by KYAN Therapeutics and/or stipulated by law after which it is de-identified or disposed of in a secure manner.
How do we keep personal information accurate and up-to-date?
We take all reasonable steps to ensure that the personal information we collect is accurate, complete and up-to-date, and also when we use or disclose it, that it is relevant.
However, the accuracy of that information depends largely on the quality of the information provided to us.
How can personal information we hold be accessed?
Individuals have a right to access the personal information that KYAN Therapeutics holds about them. We will give access to an individual’s personal information in the form they request.
However, if the situation doesn’t permit us doing so, we will, with reasonable means, provide alternative means of access or discuss how access can be given through a mutually agreed intermediary.
We will disclose the personal information and give access to the individual’s Authorized representative or legal adviser whom we have been given written authority to do so.
Please be aware that if your personal data has been provided to us by a third party (e.g. your doctor or employer), you need to contact that individual or organization directly if you have any related query or complaint.
How to contact our Data Protection Officer?
If there are any questions or feedback relating to one’s Personal Data or this policy; or a party would like to withdraw one’s consent to use of one’s Personal Data as set out in this policy; or a party would like to obtain access and/or make corrections of Personal Data records, please contact our Data Protection Officer by emailing firstname.lastname@example.org.